the association between prior exposure to lenalidomide and tp53-mutated aml/mds
Published 2 years ago • 234 plays • Length 3:39Download video MP4
Download video MP3
Similar videos
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
1:27
treatment options for patients with tp53-mutated aml
-
2:50
magrolimab in tp53 mutated aml and mds
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
3:00
apr-246 in tp53 mutated mds and aml
-
0:33
unmet needs in mds: treating relapse after allohsct & tp53-mutated disease
-
16:56
p53 mutations in cancer
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
1:03
significance of p53 mutations in aml
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
1:36
the impact of tp53 mutations in patients with myelofibrosis undergoing sct
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:15
151216 1830 the project 10 seven way paired kidney exchange
-
3:57
validation of the ipss-m risk stratification system in mds
-
24:51
connect to end progressive ms!
-
4:04
quality of life in transfusion-dependent mds
-
2:10
transplant outcomes of aml/hr-mds patients treated with sabatolimab plus hma